Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.

(00:31)
 Can you provide our listeners with a little bit of background on your role at Mayo Clinic?

(01:56)
 Is Ma2 an example of identifying a need in patient care and then creating a test to fill that gap?

(02:30)
 Can you give us an overview of the disease state?

(04:29)
 What makes testing for these antibodies so complex?

(07:08)
 What specimen types are needed? Is there anything else our listeners should know about the assay itself?

(08:18)
 Ma2 will initially be a standalone test. But will these antibodies eventually be included in the movement disorder and encephalopathy tests?

(09:30)

Is it correct that roughly 80% of these patients have a cancer?

(10:41)

What types of patients should this testing be ordered for?

(13:39)

Is rapid onset part of the presentation?

(15:53)

Should any other testing be ordered in conjunction with Ma2?

(17:18)

How important is early, aggressive treatment for these patients?

(18:49)

What are you most excited about with this test launch?